The effect of sodium-glucose cotransporter 2 inhibitors on peripheral nerves and kidneys in diabetes mellitus (DM) remains unexplored. Therefore, this study aimed to explore the effect of empagliflozin in diabetic rats. DM in rats was induced by streptozotocin injection, and diabetic rats were treated with empagliflozin 3 or 10 mg/kg. Following 24-week treatment, response thresholds to four different stimuli were tested and found to be lower in diabetic rats than in normal rats. Empagliflozin significantly prevented hypersensitivity (P<0.05) and the loss of skin intraepidermal nerve fibers, and mesangial matrix expansion in diabetic rats. Results of this study demonstrate the potential therapeutic effects of empagliflozin for the treatment of diabetic peripheral neuropathy and nephropathy.

Citations

Citations to this article as recorded by  

• Effect of empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus
  Sahar Mohamed El-Haggar, Yasser Mostafa Hafez, Amira Mohamed El Sharkawy, Maha Khalifa
  Medicina Clínica.2024;[Epub]     CrossRef
• A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy
  Osman Syed, Predrag Jancic, Nebojsa Nick Knezevic
  Pharmaceuticals.2023; 16(6): 801.     CrossRef
• Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors
  Wenwen Guo, Han Li, Yixuan Li, Wen Kong
  Biomedicine & Pharmacotherapy.2023; 165: 115025.     CrossRef
• A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy
  Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, Ebru Arioglu-Inan, Julia Weinmann-Menke, Martin C. Michel
  Pharmacology & Therapeutics.2023; 249: 108503.     CrossRef
• The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
  Jinlan Liao, Amy Kang, Chao Xia, Tamara Young, Gian Luca Di Tanna, Clare Arnott, Carol Pollock, Arun V. Krishnan, Rajiv Agarwal, George Bakris, David M. Charytan, Dick de Zeeuw, Hiddo J.L. Heerspink, Adeera Levin, Bruce Neal, David C. Wheeler, Hong Zhang,
  Diabetes & Metabolism.2022; 48(4): 101331.     CrossRef
• Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study
  Fukashi Ishibashi, Aiko Kosaka, Mitra Tavakoli
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Protective effect of empagliflozin on gentamicin-induced acute renal injury via regulation of SIRT1/NF-κB signaling pathway
  Sandy R. Botros, Asmaa I. Matouk, Aliaa Anter, Mohamed M.A. Khalifa, Gehan H. Heeba
  Environmental Toxicology and Pharmacology.2022; 94: 103907.     CrossRef
• Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling
  Noha F. Abdelkader, Marawan A. Elbaset, Passant E. Moustafa, Sherehan M. Ibrahim
  Archives of Pharmacal Research.2022; 45(7): 475.     CrossRef
• Pathogenesis and Treatment of Diabetic Peripheral Neuropathy
  Seon Mee Kang
  The Journal of Korean Diabetes.2022; 23(4): 222.     CrossRef
• Empagliflozin and neohesperidin protect against methotrexate-induced renal toxicity via suppression of oxidative stress and inflammation in male rats
  Adel T. Osman, Souty M.Z. Sharkawi, Mohamed I.A. Hassan, Amira M. Abo-youssef, Ramadan A.M. Hemeida
  Food and Chemical Toxicology.2021; 155: 112406.     CrossRef
• Effect of exenatide on peripheral nerve excitability in type 2 diabetes
  Tushar Issar, Natalie C.G. Kwai, Ann M. Poynten, Ria Arnold, Kerry-Lee Milner, Arun V. Krishnan
  Clinical Neurophysiology.2021; 132(10): 2532.     CrossRef
• Effectiveness of Empagliflozin With Vitamin D Supplementation in Peripheral Neuropathy in Type 2 Diabetic Patients
  Sanjana Mehta, Parminder Nain, Bimal K Agrawal, Rajinder P Singh, Jaspreet Kaur, Sabyasachi Maity, Aniruddha Bhattarcharjee, Jagannadha Peela, Shreya Nauhria, Samal Nauhria
  Cureus.2021;[Epub]     CrossRef
• Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis
  Ahmed M. Kabel, Remon S. Estfanous, Majed M. Alrobaian
  Respiratory Physiology & Neurobiology.2020; 273: 103316.     CrossRef
• Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition
  Nitin A. Das, Andrea J. Carpenter, Anthony Belenchia, Annayya R. Aroor, Makoto Noda, Ulrich Siebenlist, Bysani Chandrasekar, Vincent G. DeMarco
  Cellular Signalling.2020; 68: 109506.     CrossRef
• Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes
  Stephanie A. Eid, Phillipe D. O’Brien, Lucy M. Hinder, John M. Hayes, Faye E. Mendelson, Hongyu Zhang, Lixia Zeng, Katharina Kretzler, Samanthi Narayanan, Steven F. Abcouwer, Frank C. Brosius, Subramaniam Pennathur, Masha G. Savelieff, Eva L. Feldman
  Biology.2020; 9(11): 347.     CrossRef
• Pre-treatment with Empagliflozin ameliorates Cisplatin induced acute kidney injury by suppressing apoptosis
  Maaly A. Abd Elmaaboud, Ahmed M. Kabel, Mohamed Elrashidy
  Journal of Applied Biomedicine.2019; 17(1): 90.     CrossRef
• Effects of ticagrelor, empagliflozin and tamoxifen against experimentally-induced vascular reactivity defects in rats in vivo and in vitro
  Yasmin Moustafa Ahmed, Basim Anwar Shehata Messiha, Mahmoud El-Sayed El-Daly, Ali Ahmed Abo-Saif
  Pharmacological Reports.2019; 71(6): 1034.     CrossRef
• SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
  Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun, Liming Chen
  Cardiovascular Diabetology.2019;[Epub]     CrossRef
• Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
  Sungjin Chung, Soojeong Kim, Mina Son, Minyoung Kim, Eun Sil Koh, Seok Joon Shin, Seung-Hyun Ko, Ho-Shik Kim
  Frontiers in Physiology.2019;[Epub]     CrossRef